West Pharmaceutical Services has sold the rights and facilities for its SmartDose 3.5 mL On Body Delivery System to AbbVie. The transaction shifts ownership of this specific large-volume wearable injector platform while West retains other SmartDose lines, including the 10 mL system, and continues to focus on higher-value drug delivery platforms such as GLP-1 related devices and larger-volume on-body systems. The deal is seen as a portfolio clean-up that reduces operational complexity and tightens the company's focus on areas with stronger growth potential. Investors may watch for how West backfills the divested capacity and whether the move improves margins and competitive positioning in injectable delivery.
West Pharmaceutical Services IncSells SmartDose 3.5 mL rights and facilities, reducing complexity and focusing on higher-growth platforms.
AbbVie IncAcquires SmartDose 3.5 mL wearable injector platform, expanding drug delivery capabilities.